	Juha Punnonen, et al. Application No.: 09/760,388 Page 2	
BI	25. (Amended Twice) The method of claim 23, wherein the dendritic cell substantially lacks IL-12 production or induces or promotes differentiation of T cells to Th0 and/or Th2 cells, as compared to a dendritic cell produced by culturing a population of peripheral blood or bone marrow mononuclear cells in IL-4, GM-CSF, and a culture medium comprising RPMI.	
B 2	27. (Amended Twice) The method of claim 23, wherein the dendritic cell comprises one or more of the following characteristics: substantially lacks expression of CD1a cell surface marker, substantially lacks IL-12 production, exhibits increased IL-10 production, and induces or promotes differentiation of T cells to Th0 and/or Th1 cells, as compared to a dendritic cell produced by culturing a population of peripheral blood or bone marrow mononuclear cells in IL-4, GM-CSF, and a culture medium comprising RPML	
B 3	29. (Amended Twice) The method of claim 28, wherein the CD83 <sup>+</sup> dendritic cell comprises one or more of the following characteristics: substantially lacks production of IL-12, exhibits increased IL-10 production, substantially lacks expression of CD1a cell surface marker, and induces or promotes Th0 and/or Th2 differentiation of T cells, as compared to a dendritic cell produced by culturing a population of peripheral blood or bone marrow mononuclear cells in IL-4, GM-CSF, and a culture medium comprising RPMI.	
B 4	68. (Amended Twice) A monocyte-derived dendritic cell, wherein the dendritic cell comprises one or more of the following characteristics: does not substantially express CD1a cell marker, substantially lacks IL-12 production, exhibits increased IL-10 production, and promotes differentiation of T cells to Th0 and/or Th1 cells.	
B 5	70. (Amended) A population of monocyte-derived dendritic cells produced by culturing a population of monocyte cells in interleukin-4 (IL-4), granulocyte macrophage colony stimulating factor (GM-CSF), and a culture medium comprising insulin, transferrin,	

Juha Punnonen, et al.

Application No.: 09/760,388

Page 3

linoleic acid, oleic acid, and palmitic acid, the monocyte-derived dendritic cells comprising an altered cytokine profile compared to dendritic cells produced by culturing a population of monocyte cells in IL-4, GM-CSF, and a culture medium comprising RPMI.

71. (Amended) The population of monocyte-derived dendritic cells of claim 70, wherein said monocyte-derived dendritic cells comprise one or more of the following characteristics: produce substantially less interleukin-12 (IL-12), produce substantially more IL-10, express less CD1a cell surface marker, and induce or promote increased T cell differentiation to Th0 or Th2 subtype, as compared to a population of dendritic cells produced by culturing a population of monocyte cells in IL-4, GM-CSF, and a culture medium comprising RPMI.

In accordance with the requirements of 37 C.F.R. § 1.121, a marked up version showing the changes to the claims is attached herewith as Appendix A. For the Examiner's convenience, a complete claim set of the currently pending claims is also submitted herewith as Appendix B. These amendments are fully supported by the specification, introduce no new matter, and are made without prejudice and are not to be construed as any abandonment of the previously claimed subject matter or agreement with any objection or rejection of record.

## **REMARKS**

Claims 1-35, 37-42, 44-68, and 70-78 are presently pending with entry of this amendment. Claims 25, 27, 29, 68, 70 and 71 have been amended herein.

Applicants thank the Examiner for his careful review of the Preliminary

Amendment mailed on April 10, 2001. The Examiner found that the amendment was incomplete because amended claim 68 did not comply with the requirements of 37 CFR 1.121. Specifically, the Examiner found that claim 68 was improperly amended because the phrase "Th0 and/or Th1" was added without being identified in the marked-up version of the claim. This was an inadvertent typographical error. Applicants hereby submit a newly amended claim 68, including a proper marked-up version of amended claim 68 (set forth in Appendix A). As indicated in the previously filed Preliminary Amendment, the amendment to claim 68 is fully supported by the